This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 859001

 

Mike Karim, CEO, commented:

 

‘We are delighted to have won this prestigious grant from the European Commission after going through the rigorous application and presentation in front of industry experts.

 

This will help drive our research and development activities, including part of our first in human study on our journey to regulatory approval and commercialisation of our next generation Flow Diverter, OxiFlow™️. This innovative medical device is designed to treat brain aneurysms, overcoming challenges of existing technology and will offer hope to patients around the world suffering from this disease.

 

I would like to thank the tireless work of our inventors and development team for their great achievements so far, our supportive board of directors and our investors who continue to have faith in our work’.